Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Sep 8;15(9):e0238323. doi: 10.1371/journal.pone.0238323

Assessment of effectiveness of DAMaN: A malaria intervention program initiated by Government of Odisha, India

Madhusmita Bal 1, Arundhuti Das 1, Jyoti Ghosal 1, Madan Mohan Pradhan 2, Hemant Kumar Khuntia 1, Sanghamitra Pati 1,#, Ambarish Dutta 3,#, Manoranjan Ranjit 1,*,#
Editor: Luzia Helena Carvalho4
PMCID: PMC7478908  PMID: 32898853

Abstract

India, a persistently significant contributor to the global malaria burden, rolled out several anti-malaria interventions at the national and state level to control and recently, to eliminate the disease. Odisha, the eastern Indian state with the highest malaria burden experienced substantial gains shown by various anti-malaria initiatives implemented under the National Vector-borne Disease Control Programme (NVBDCP). However, recalcitrant high-transmission “pockets” of malaria persist in hard-to-reach stretches of the state, characterised by limited access to routine malaria surveillance and the forested hilly topography favouring unbridled vector breeding. The prevalence of asymptomatic malaria in such pockets serves as perpetual malaria reservoir, thus hindering its elimination. Therefore, a project with the acronym DAMaN was initiated since 2017 by state NVBDCP, targeting locally identified high endemic ‘pockets’ in 23 districts. DAMaN comprised biennial mass screening and treatment, provisioning of long-lasting insecticidal net (LLIN) and behavioural change communication. Subsequently, to inform policy, assessment of DAMaN was conceived that aims to estimate the coverage of the various components of the project; the prevalence of malaria, even at sub-patent level especially among pregnant/lactating women and children; and its impact on malaria incidence. A survey of DAMaN beneficiaries will measure coverage; and knowledge and practices related to LLIN; along with collection of blood specimens from a probability sample. A multi-stage stratified clustered sample of 2228 households (~33% having pregnant/lactating women) will be selected from 6 DAMaN districts. Routine DAMaN project data (2017–2018) and NVBDCP data (2013–2018) will be extracted. Rapid Diagnostic Test, Polymerase Chain Reaction and blood smear microscopy will be conducted to detect malarial parasitemia. In addition to measuring DAMaN’s coverage and malarial prevalence in DAMaN pockets, its impact will be estimated using pre-post differences and Interrupted Time Series analysis using 2017 as the “inflection” point. The assessment may help to validate the unique strategies employed by DAMaN.

Introduction

Malaria, the age-old mosquito borne parasitic disease, remains a substantial health problem in many parts of the world, especially in the tropical developing nations. The Millennium Development Goal-4 [1] followed by the Sustainable Development Goals -3 [2] of the United Nations trained their focus on malaria, as because it is a key contributor towards global burden of mortality and morbidity, especially among children under five years of age (under-5), a key segment of the population for the developmental goals. To attain this, World Health Organization (WHO) adopted the comprehensive Global Technical Strategy, with an aim to reduce malaria incidence and mortality rates by at least 90%, worldwide, by 2030 [3].

India is one of the 11 high malaria burden countries in the world. Along with Sub-Sahara African countries it contributes to 85% of global malaria burden, despite a sharp reduction (28%) of malaria cases from 2017 to 2018 in the country [4]. India has expansive geography and diverse climate; therefore, its certain regions provide an ideal environment for sustaining malaria parasites and their vectors [5]. Ambient temperature, relative humidity, forested hilly topography and extended rainy season of these regions favour malaria transmission. Eventually, in Odisha, an eastern coastal state of India, especially in its two geo-physical regions (the Eastern Ghats and Northern plateau), such conditions [6] abound. Therefore, it is not surprising that the endemicity of malaria in Odisha has always been significantly high historically [79] as it contributed to 40% of the countries’ total burden of malaria in 2017 [10].

In India, many programmes have been rolled out nationwide to prevent and control malaria since independence. The National Malaria Control Program (NMCP) was launched in 1953 and delivered astounding results within a five-year period. Thereafter, NMCP was renamed to National Malaria Eradication Program (NMEP) in 1958 with a view to eliminating the disease entirely from the country. However, unfortunately, malaria staged a huge comeback in India as the anti-malaria resources were prematurely withdrawn after the initial remarkable successes of the ‘50s and ‘60s. This surge in malaria led to the launch of Modified Plan of Operation in 1977 with an eye towards reduction of the disease burden in a cost-effective and integrated manner. Time to time malaria action plan was further updated, as in 1995, when emphasis was given on the use of revised drug schedule in high-risk areas as effectivity of traditional anti-malaria drugs were on the wane. With further change in policy, the programme was renamed as National Anti-Malaria Programme (NAMP) in 1999. Later in 2002 the National Vector Borne Disease Control Program (NVBDCP) put other vector borne diseases of national concern along with malaria under one umbrella for optimum utilisation of manpower and resources. In 2005, an Intensified Malaria Control Project was launched with the assistance of Global Fund for AIDS, Tuberculosis and Malaria in North Eastern states and Odisha, Jharkhand and West Bengal [11]. It introduced new interventions for case management and vector control, namely Rapid Diagnostic Tests (RDT) (2005), Artemisinin-based Combination Therapy (ACT) (2006) and Long Lasting Insecticidal Nets (LLINs) (2009) [12]. These were then significantly reflected in the Strategic Plan for Malaria Control in India for 2012–2017. Robust methods of monitoring and evaluation were also incorporated into the programme, to track the new interventions [13].

Meanwhile, given the gravity of the problem, malaria always received priority in Odisha, which instituted anti-malaria initiatives in tandem with national measures. As mentioned above, after an initial reduction in reporting of malarial cases due to early success of NMCP, a resurgence of malaria was observed since 1967 in the state. After which many significant schemes were launched that helped to shore up the state public health machinery to fight against the disease, again in line with the renewed efforts instituted by the national government. Regardless of all these efforts, malaria endemicity in the state remained obstinately high. A feature that consistently stood out is that malaria control in large swathes of Odisha is operationally difficult, as significant portion of the land has hilly terrain, forest cover with poor communication facilities along with left-wing extremism; and a large section of the residents of these hard-to-reach areas are indigenous tribal people [7], who often live in widely scattered small hamlets. This historically has been rendering many such malaria endemic villages poor accessibility to malaria services [14].

In 2007, the Odisha Health Sector Plan (OHSP) aided by the Department for International Development (DFID) of the United Kingdom was rolled out [15]. The components of the intensified anti-malaria strategies under OHSP included integrated vector control measures, mass use of RDT and ACTs for diagnosis and treatment, service decentralization (working through village-level Accredited Social Health Activist–ASHA), behaviour change communication (BCC), improved surveillance, and inter-sectorial convergence. The “Mo Masari”, meaning “our bed net” scheme of OHSP was also rolled-out to promote the use of LLINs among the pregnant women and tribal residential school children in 7 high malaria endemic districts of the state [16]. In tribal villages traditional folk-art based methods were used for knowledge dissemination. Subsequently during 2008 to 2013 these intensified anti- malarial activities in the state helped to reduce > 44% notification of malaria [15]. However, this decline could not be sustained in the consecutive years (Fig 1) especially in the districts having high forest cover and many hard-to-reach areas.

Fig 1. Odisha Annual Parasite Incidence (API) status of the year 2013 and 2016.

Fig 1

The data originated from Balk, D., M. R. Montgomery, H. Engin, N. Lin, E. Major and B. Jones. 2020. Spatial Data from the 2011 India Census. Palisades, NY: NASA Socioeconomic Data and Applications Center (SEDAC). https://doi.org/10.7927/gya1-wp91. Accessed 29 July 2020. No copyrighted material was used. The data was further modified using QGIS software version 3.4.13.

In 2013, the Comprehensive Case Management Project (CCMP), an operational research initiative, was started by NVBDCP, Odisha in collaboration with National Institute of Malaria Research, with support from Medicines for Malaria Venture and WHO [14]. CCMP showed that high endemic hard-to- reach villages had sub-optimal malaria surveillance, often displaying misleadingly low reporting of cases due to under-detection, and thus ultimately leading to persistence of malaria reservoir in those pockets. Majority of such persistent cases were found to be afebrile or asymptomatic, therefore not seeking routine malaria care, making them even more critical to local malaria transmission as they would not be identified by routine malaria surveillance system. CCMP also demonstrated that mass screening and treatment in this hard-to-reach, forest covered areas can be remarkably useful in detection and treatment of such asymptomatic/ afebrile malaria cases. Another similar study conducted in hard-to-reach areas of southern districts of Odisha went on to illustrate that detecting and treating afebrile malaria in under-5 children in hard-to-reach areas improved growth, anaemia and malaria case load [17].

From these observations it became imperative that in order to achieve malaria elimination in Odisha, asymptomatic malaria cases residing in these hard-to-reach areas of the state have to be identified and treated in order to contract the persisting malarial reservoirs. Meanwhile, the usefulness of LLIN from previous experience in the state also led planners to include this tool in a comprehensive package, which was then conceived by the state government as a large-scale innovative project called “Durgama Anchalare Malaria Nirakarana (DAMaN)” (English translation: “Malaria Elimination in Remote Areas”) in 2017. The main objective of DAMaN was to supplement the routine malaria control activities and fill the gaps in case finding and treatment as well as vector control in the high-endemic remote pockets of the state. In 2017, this massive public health initiative was rolled out in the hard-to-reach pockets of 23 high malaria burden districts of the state, targeting roughly a population of 1 million residing in 7000 far-flung villages. The three pillars of the DAMaN strategy included 1) mass screening (screening of all residents) by using bivalent RDT followed by treatment of RDT-positive cases in a “camp approach”—referred to as Mass Screening and Treatment (MSAT), 2) vector control measures that included LLIN distribution and promotion, and lastly 3) community mobilisation. Table 1 summarises the aims and approaches of DAMaN.

Table 1. Aims and approaches of DAMaN.

Aims of DAMaN Approach Target population Identification of target population
To reduce the malaria parasite load including number of gametocytes in the human population, especially among asymptomatic/afebrile cases MSAT in camp approach twice a year Underserved population in hard-to-reach villages/hamlets, many of whom are asymptomatic/afebrile Through local NVBDCP network who have local knowledge and based on historic NVBDCP case notification
To kill the anopheles vector mosquitoes and to provide personal protection to the villagers from mosquito bites so as to break the “human-mosquito-human” cycle LLIN distribution and promotion Population in hard-to-reach areas and also otherwise high endemic “pockets”. Entire population of all villages was protected by LLIN. For this each household was given adequate numbers of LLIN depending upon the number of people in the house hold (one LLIN per 1.8 People). NVBDCP case notification rates
To mobilize the community and carry out BCC for DAMaN so that the target population utilizes the service packet of DAMaN Village contact drive, school sensitization and Malaria Shamadhan Sivira (MSS) Underserved population in hard-to-reach villages/hamlets Local NVBDCP network

The MSAT operations of DAMaN were planned to be carried out mainly through ASHA and village-level community volunteers twice a year under the supervision of health workers and health supervisors, first during pre- monsoon (March-April-May) when the entire population in the target villages/hamlets were to be covered and second during post-monsoon season (October-November) when only pregnant women and children from the target villages/hamlets were to be screened and treated.

DAMaN is a massive new public health initiative to control malaria in high endemic and hard-to-reach underserved areas. It entailed an investment of 10 crore Indian Rupees (1333591 US dollars) per year, which is a significant amount for a relatively resource-constrained state like Odisha. Early results show that implementation of DAMaN coincided with drastic reduction of case notification in high endemic districts [10]. Therefore, an exercise was conceptualised to comprehensively assess the DAMaN project (hereinafter referred to as DAMaN Assessment); its effectiveness and suggest mid-course corrections if found necessary. DAMaN Assessment is also of immense significance as it would categorically evaluate and validate the effectiveness of the various components of DAMaN, so that its successful pieces can be further replicated in other malaria endemic region of the country or around the globe.

The main objectives of the DAMaN Assessment include

Estimation of the coverage of the three main components of DAMaN that includes mass screening and treatment (MSAT), vector control measures (LLIN and/or IRS) and community mobilisation and participation.

Estimation of the serial prevalence of malaria parasites at clinical and sub- clinical (asymptomatic and sub-patent) level of parasitemia.

Evaluation of the impact of DAMaN on fever and malaria burden as reflected in NVBDCP data.

Assessment of the prevalence of maternal and child health in terms of birth outcome, anaemia in pregnancy and nutritional status of under five children among DAMaN beneficiaries and compare with state averages.

Methodology

Approaches and design of the DAMaN Assessment

Table 2 summarises the various objectives of DAMaN Assessment and the approaches to address each objective.

Table 2. The objective(s), approaches and study design of the DAMaN Assessment.

Objectives Approaches and study design
1. To estimate the coverage of the three main components of DAMaN that includes 1a. Coverage of MSAT, a component of DAMaN will be estimated along with MSAT’s test positivity rate proportion of asymptomatic among positives etc. This will be done from DAMaN project information system data.
a) mass screening and treatment (MSAT), 1b. A survey of DAMaN beneficiaries to be conducted (details below) and primary data from the survey will be used to estimate Long lasting Insecticidal Net (LLIN) usage and coverage of Indoor Residual Spray
b) vector control measures (LLIN) and c) community mobilisation and participation 1c. Same data as 1b will be used to estimate coverage by DAMaN-related community mobilisation campaigns
2. To estimate the prevalence of malaria parasites at clinical and sub-clinical (asymptomatic and sub-patent) level 2a. Secondary data, related to MSAT, collected from DAMaN project information system for 2017 to 2019. This will help to track the trend of prevalence in parasitemia
2b. DAMaN survey will include collection of blood specimens from the sampled individuals and tests to identify parasitemia and quantification of parasite gametes will be carried out. Two rounds of the survey is to be conducted which will help us to track the trend in parasitemia prevalence
3. To evaluate the impact of DAMaN on fever and malaria burden as reflected in routine NVBDCP data Routine yearly and monthly NVBDCP data, collected from the level of the Sub-Centres, the lowest reporting units of the programme, for blood examination rate and parasite incidence for the six survey districts from 2013 to 2018 (6 years) will be analysed using appropriate variants of Difference analysis, Difference analysis across three categories of Sub-Centre stratified by the scale of DAMaN’s MSAT coverage, interrupted time-series (ITS), ITS analysis across three strata of sub-center. The sub-centres then will be stratified by their DAMaN project’s MSAT coverage data (see point 1). Then trends of NVBDCP data will be compared across the strata of Sub-Centres (hypothesis: “higher the coverage of DAMaN, steeper is the decline of malaria and fever incidence”)
4. To assess the maternal and child health in terms of birth outcome, anaemia in pregnancy and nutritional status of under five children among DAMaN beneficiaries and compare with state averages A survey of DAMaN beneficiaries will be conducted and primary anthropometric, haemoglobin and pregnancy outcome indicators will be estimated. It will be compared with state averages of Odisha

Ethical approval

The study has been approved by both the Institute Human Ethical Committee (ICMR-RMRC/IHEC-2019/012 dated 27/02/2019) and Research & Ethics Committee of Department of Health and Family Welfare, Govt. Of Odisha (453 /SHRMU /187 /17 Dated 22/8/2017). DAMaN project data will be extracted in aggregate form and no individual-level data will be retrieved or used, therefore there is no need for de-identification of DAMaN project data. There is also no plan to access patient medical records. Survey data and blood specimen will be collected after written consent/assent is taken from each participant. The raw survey data will be under the secure custody of the principal investigator and the data will be completely de-identified for analysis.

Survey

A survey of DAMaN beneficiaries and their households is to be carried out to collect primary data on these individuals, which will also include collection of their blood specimens. A probability representative sample of the DAMaN beneficiaries will be drawn for the survey the calculation of the size and sampling technique of which are described below. The survey will be conducted from the month of August to November, which synchronies with the period of DAMaN implementation.

Sample size

The sample size of households (each containing pregnant/lactating women) for survey has been estimated using the formula, n = [DEFF*Np(1-p)]/ [(d2/Z21-α/2*(N-1)+p*(1-p)], where the rarest event that needs to be examined in this survey is parasitemia in pregnant/lactating women and in areas with relatively low endemicity among DAMaN-covered villages it is assumed to be around 3%. Additionally, 1% absolute precision, Z score corresponding to 95% Confidence Interval that is 1.96, with design effect 2 have been applied to this calculation. Therefore, the sample size of households to be surveyed is 2228. Only the household head (also pregnant and lactating mother) will be interviewed per household. However, blood specimens will be collected from all members in the household present at the time of the interview.

The sample size calculation was based on two assumptions. The first being the prevalence of parasitemia among pregnant/lactating women in DAMAN areas being 3% and the second, pregnant women making up 1.5–2% of the population and 0–59 months old children making up approximately 10%. Hence, the prevalence of other more common events in other sub-population such as under-5s can be estimated using this sample conveniently.

Sampling strategy

The broad sampling strategy to be followed is multi-stage clustered sampling technique. The various levels of sample elements and their clustered nature, relevant for this study can be seen in figure below (Fig 2).

Fig 2. The various levels of sample elements and their clustered nature data.

Fig 2

Data

Four types of data will be used for DAMaN Assessment which are as described below. A pretested, validated questionnaire inspired by that used in National Family Health Survey fourth round, 2015–2016 (NFHS-4) is to be applied to capture household and individual-level data, which is to be answered by the household head. The questionnaire consists of many sections, namely, the demographic and household information, the socio-economic characteristics and knowledge and practices of general malaria, vector control and treatment of fever cases. The questionnaire also will contain information on pregnant and lactating mother. At least 1 ml of intra-venous blood specimen will be collected for malaria and haemoglobin analysis and anthropometric measurements will be recorded from all the members of the sampled household present at the time of the interview. Pregnant women sampled in the survey will be followed-up longitudinally till their birth outcome can be recorded. The variables of the different survey components are listed in the Table 3.

Table 3. Summary of the survey variables.

Survey Components Types of tool Variables
Section I: Demographic and household information 12 questions Demographic characteristics of all the sample household members will be collected in this section. Information on household members covered in malaria screening conducted under DAMaN project will also be recorded.
Section II: Anthropometry 3 measurements Height, weight, Mid-Upper Arm Circumference (MUAC) of the household members will be measured.
Section III: Socio-economic characteristics 13 questions Information on the assets owned by the beneficiary will be asked in order to analyse their socio-economic status of the household.
Section IV: Knowledge and awareness of malaria 15 questions This will include questions on awareness and knowledge of malaria, along with questions on health care seeking practices related to malaria.
Section V: Vector control 10 questions Questions related to vector control measures taken through the DAMaN project will be asked along with the usage pattern of mosquito nets
Section VI: Fever cases 2 questions Details of the family member who had fever at any time in the two weeks preceding the survey will be noted in this section.
Section VII: Information on pregnant and lactating mothers 8 questions Data regarding pregnancy history and birth outcome along with birth weights will be gathered in this section.
Section VIII: Blood Marker 4 tests on blood specimens of all survey participants Rapid Diagnostic Test (RDT), Polymerase Chain Reaction (PCR), Microscopy and Complete Blood Count (CBC) will be done with the blood specimen collected from surveyed population. (details below)

DAMaN project information system data

DAMaN project data will be extracted from the six sampled districts for the years 2017 to 2019. This will contain village-wise data of MSAT carried out by DAMaN. Among positive cases whether they are symptomatic (Y/N) and the type of parasite(s) (P falciparum or P Vivax or both) will also be noted in addition to their demographic (age, sex and other) data.

NVBDCP routine data

Both yearly and monthly Sub-Centre (SC—the most peripheral health outpost in the Indian health system) wise routine NVBDCP data will be collected from the six sampled districts of Odisha that would contain parasite incidence and blood examination rate, disaggregated by age, sex and type. The data of 7 years (2013 to 2019) will be collected and the period 2013–2017 will be considered pre-DAMaN phase and 2018–2019 post-DAMaN.

National Family Heath Survey 4 (NFHS-4) factsheet

The Odisha averages of Hb/anaemia, birth outcomes and anthropometry in the general population, pregnant/lactating women and children of Odisha will be extracted from the state-wise factsheet of NFHS-4 that was conducted in 2015–2016 [18].

Laboratory investigation

The laboratory analysis will consist of four tests of the blood specimen collected from surveyed participants.

Three diagnostic methods, namely Rapid Diagnostic Test (RDT), blood smear microscopy, polymerase chain reaction (PCR) will be used to find the prevalence of malarial parasites in the blood specimen collected. This modus operandi will ensure an exhaustive investigation for detecting parasitemia. The Histidine-Rich Protein 2 (PfHRP2) gene deletion in Plasmodium falciparum leads to no-detection in RDT, however Pf prevalence in those cases can be captured using microscopy and PCR. The PCR method will also be helpful in detecting parasite at sub-microscopic level, which usually gets missed out by RDT and microscopy.

Rapid Diagnostic Test (RDT)

Primary screening of the malaria infection will be performed by using RDT (Pf/PAN malaria antigen) and microscopy followed by PCR for confirmation and species identification. The RDTs to be used in our study detects Histidine-Rich Protein 2 (PfHRP2) from P.falciparum and Parasite-Specific Lactate Dehydrogenase (pLDH) from the parasite glycolytic pathway found in all species. The RDT will assist in finding P. falciparum infection and/or a mixed infection. Mixed infection implies presence of more than one species of Plasmodium in the individual. The sensitivity and specificity of the kit is 98.72% and 96.76% respectively.

Blood smear microscopy

Both thick and thin blood smears will be prepared for diagnosis and species identification of malaria parasites within 24 hours of blood collection. Briefly blood smears will be fixed with methanol (thin smear only) and stained with Giemsa stain. Smears will be examined microscopically and graded for the presence/absence and species of Plasmodium.

Polymerase Chain Reaction (PCR)

To confirm ICT and/or microscopy results and detect parasites below the limit of microscopy (around 40 parasites/ml of blood) a retrospective, species-specific PCR will be carried from each blood samples. The DNA will be extracted from the blood sample using Qiagen DNA mini kit (Quigen,West Sussex,UK). Separate reactions will be carried out using species-specific (P.falciparum, P.vivax, P.ovale, P. malariae) oligonucleotide primers with every sample for the detection of each species in a reaction volume of 20μl as described by others [19] and regularly performed in our laboratory for routine malaria diagnosis. The PCR amplified products will be separated by electrophoresis on 2% agarose gel with added ethidium bromide (0.5μg/ml). Gels will be visualised and processed using gel documentation system.

Haematological analysis

Haemoglobin estimation as a part of the complete blood cell count (CBC) will be done in automatic haematological analyser (Melet Schloesing Laboratories, USA) within 24 hour of collection of whole blood in EDTA.

Statistical analysis

Descriptive statistics

Age and education will be categorized from quantitative variables. Body Mass Index (BMI) (weigh in kg/height in m2) will be categorized into underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2) and overweight/obese (> 25 Kg/m2). Stunting (height for age, Wasting (weight for height) and underweight (weight for age) will be defined as mild/moderate, or severe when their values are < -2 Standard Deviation (SD) and < -3SD respectively from the median value of the WHO Child Growth Standards for under-five children. The household-level wealth index is to be based on the recorded assets and housing and sanitation facilities. Principal component analysis will be used to derive a single wealth index from these multiple variables, which will be then used as a quantitative variable and also categorized into five quintiles to be used as an ordinal variable. Anaemia will be defined using WHO (2001) prescribed cut-off values (Table 4).

Table 4. Haemoglobin cut-off values used to define anaemia.
Reference group Non-Anaemia (g/dl) Categories of Anaemia (g/dl)
Mild Moderate Severe
Children 6–59 months of age 11 & above 10–10.9 7–9.9 <7
Children 5–11 years of age 11.5 & above 11–11.4 8–10.9 <8
Children 12–14 years of age 12 & above 11–11.9 8–10.9 <8
Non-pregnant women (15 years of age and above) 12 & above 11–11.9 8–10.9 <8
Pregnant women 11 & above 9–10.9 7–9.9 <7
Men (15 years of age and above) 13 & above 11–12.9 8–10.9 <8

Summary statistics will be used to describe the various features of primary study sample and prevalence of anaemia, various measures of undernutrition and prevalence of malaria infection in the sample population. The descriptive statistics will also summarise LLIN coverage and usage, IRS activities and malaria-related knowledge and practices in the sampled DAMaN villages. The relevant indicators from DAMaN survey data will be compared with that of Odisha state averages extracted from NFHS-4 factsheet [18].

Statistics such as test coverage, test-positivity and asymptomatic among positives will be used to summarise DAMaN project data, which will be aggregated at the sub-district (block) level for the six sampled districts of DAMaN Assessment.

Difference analysis

The difference in average annual case notification (also known as Annual Parasite Incidence) between post-DAMaN (2018–2019) and pre- DAMaN (2013–2017) will be computed using a Poisson regression framework as positive malaria cases notified is count data which approximates a Poisson distribution. The equation has been explained below.

log(y)=β0+β1x+offset(log(population))+ε (1)

y = annual count of malaria cases notified

x = phase expressed as 0, 1; where 0 indicates pre-DAMaN and 1 indicates post-DAMaN.

β1 is the parameter of interest—the exponentiated value of which will give the ratio of average annual case notification in post-DAMaN: pre-DAMaN phases.

Difference analysis across three categories of sub-centre stratified by the scale of DAMaN coverage

The initial equation to test whether the ratio of average annual case notification in post-DAMaN: pre-DAMaN phases vary across the three categories of sub-centre significantly is as follows:

log(y)=β0+β1x1+β2x2+β3x1*x2+offset(log(population))+ε (2)

Where:

y = annual count of malaria cases notified

x1 = time period / intervention phase expressed as 0, 1; where 0 indicates phase 1 and 1 indicates phase 2.

x2 = a categorical variable indicating three strata of sub-centres (0 = no DAMaN coverage, 1 = below median coverage, 2 = above median coverage)

x1*x2 = indicates the interaction between phase and the intervention status.

Log(population) of the SC will be used as the offset variable in the equation.

Greek letters β0, β1, β2 and β3 are all unknown parameters to be estimated and ε is a random, unobserved ‘error’ term.

The coefficients:

β3 the focus is whether this parameter is significant or not.

If found significant then using Eq (1) annual case notification ratios will be estimated for three strata of sub-centres separately to observe whether coverage by DAMaN (the stratifying variable) is related to decline in cases.

Interrupted time-series analysis

Sub-centre-wise monthly time-series data, of cases notified and blood specimens examined routinely by NVBDCP, will be dealt with interrupted time-series analysis approach that will use a segmented Poisson regression framework. The count outcome data will be regressed over time to estimate the “trend” of these indicators. The trend will be “segmented” that is divided by an “inflection” (interruption) point, which corresponds to 2018 after DAMaN was rolled out in 2017. Immediate changes in “level” of the trend lines across the inflection point will also be estimated.

The segmented regression equation to be used in the ITS analysis will be:

log(y)=β0+β1x1+β2x2+β3x1*x2+offset(log(population))+ε (3)

Where:

y = count of outcome indicator

x1 = time since the start of the study

x2 = phase expressed as 0, 1; where 0 indicates phase 1 and 1 indicates phase 2.

x1*x2 = represent interaction term

β1 = the slope of pre-intervention.

β2 = exponentiated value represents the change in the “level” (immediate change) following the introduction of the intervention expressed as ratio of immediate shift in monthly case detection post-DAMaN: pre-DAMaN

β3 = exponentiated value represents the difference between slopes between two phases of intervention (long-term change) expressed as ratio of trends in monthly case detection post-DAMaN: pre-DAMaN

Interrupted time-series analysis across three strata of sub-centre

We will test whether the post-DAMaN: pre-DAMaN “slope” or “level” changes are significantly different across three categories of sub-centre using a segmented Poisson regression for which the equation is following:

log(y)=β0+β1x1+β2x2+β3x3+β4x1*x2+β5x2*x3+β6x1*x3+β7x1*x2*x3+offset(log(population))+ε (4)

Where:

y = count of outcome indicator

x1 = time as a continuous variable since the start of the data collection

x2 = phase expressed as 0, 1; where 0 indicates phase 1 and 1 indicates phase 2.

x3 = a categorical variable indicating three strata of sub-centres

x1*x2; x2*x3; x1*x3 = indicates two-way interactions respectively

x1*x2*x3 = three-way interaction between time, phase and intervention status

Log(population) of the SC will be used as the offset variable in the equation.

The coefficients of interest in ITS:

β6 = is the first parameter of interest whether the variations in “level” changes are statistically significant or not across the three strata of sub-centres

β7 = is the second parameter of interest whether the variations in “slope” changes are statistically significant or not across the three strata of sub-centres

If these parameters are significant then stratified interrupted time-series analysis using segmented Poisson regression (Eq 3) will be carried out in three strata of sub-centres separately.

All these 4 types of model will also be repeated with “blood examination” as the outcome.

R statistical software version 3.5.1 [20] will be used for all analyses. Specifically, WHO anthro package for R will be used to calculate the anthropometric measurement (stunting, wasting and underweight) for under five children.

Discussion

The DAMaN intervention project is the first-of-its kind in the country targeting malaria elimination in hard-to-reach “pockets” of high malaria-burden district of the state by Government of Odisha. The proposed DAMaN Assessment will provide evidence on the impact and outcome of intervention based on reduction in overall parasite load and reduction/interruption in transmission and changes in important key health indicators. The study will also capture information on the maternal and child health as evidences exist that prolonged exposure to malaria has impacts on maternal health, pregnancy outcome, nutritional status and anaemia level of children under the age of five [21, 22]. Molecular investigation, another integral component of DAMaN Assessment, will determine not only the distribution of different species of Plasmodium in these areas even at sub patent level but also elucidate the changes of their behaviour as well as adaptation (if any) due to rigorous drug pressure as shown previously [23]. The extent of DAMaN coverage will help the programme managers of the project to realize the immediate output and course correction measures required, wherever necessary for their efforts, and in the long run will help to predict the ideal coverage required in order to arrest the transmission of malaria in Odisha. Overall DAMaN Assessment will validate the measures implemented to eliminate malaria in these high burden remote areas of the state. The results of the study will inspire replication of the project in other parts of the country with similar malaria burden and topographic hindrance. The methodology emanating from this study could also be applicable in assessing the impact of other national/state projects related to elimination of other vector-borne diseases.

Supporting information

S1 File. Survey questionnaire.

(PDF)

Acknowledgments

We would like to thank Dr. Prameela Baral, Addl. Director of Health Services (VBD), Odisha, Dr P K Sahu, Nodal Officer NVBDCP-Odisha, Dr Kirti Mishra, Mr Debakanta Sandhibigraha and administration of the Department of Public Health, Odisha for supporting us with information about the processes and data sources of the DAMaN intervention project, which will be used for the assessment exercise in future.

Data Availability

All relevant data from this study will be made available upon study completion.

Funding Statement

The research grant was received by MR, MB, AD and SP. Funding received from: Department of Health and Family Welfare, Govt. Of Odisha (DHS:2244/DAMaN/Project proposal/18-19/31.12.2018) https://health.odisha.gov.in The funder will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Decision Letter 0

Luzia Helena Carvalho

12 Jun 2020

PONE-D-20-12484

Assessment of effectiveness of DAMaN : A malaria intervention program initiated by Government of Odisha, India

PLOS ONE

Dear Dr. Ranjit,

Thank you for submitting your manuscript for review to PLoS ONE. After careful consideration, we feel that your manuscript will likely be suitable for publication if the authors revise it to address specific points raised by the reviewer.  According to reviewers, there are some specific areas where further improvements would be of substantial benefit to the readers, including sample size calculation. Additionally, the authors should clarify about critical variables that may impact malaria control, such as the annual variation in rainfall and the fluctuation of vector density.

Please submit your revised manuscript by July 10.  If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Luzia Helena Carvalho, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.  Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information."

3. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria applied to participant recruitment, c)  descriptions of where participants will be recruited and where the research will take place. Moreover, in ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records (DAMan project data) that will be used in the  retrospective part of study. Specifically, please ensure that you have discussed whether all data will be fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.'

4. PLOS ONE does not permit references to unpublished data; therefore, we request that you either include the referenced data or remove the instances of "data not shown," "unpublished results," or similar.

5. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

a) The name of the colleague or the details of the professional service that edited your manuscript

b) A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

c) A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

6. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: PONE-D-20-12484

Title: Assessment of effectiveness of DAMaN: A malaria intervention program initiated by Government of Odisha, India

Article Type: Registered Report Protocol

General Comments: This study aims to assess the impact of a special programme launched in Odisha state of India to flush out asymptomatic malaria by biannual mass surveillance programme and of the mass distribution of long lasting insecticide nets (LLINs) on overall malaria incidence in the state. For the same, authors’ have proposed to divide malarious districts in to three strata based on 2016 malaria data (figure 1).

Specific Comments:

1. Figure 2 suggests that two districts are already selected from each of the three strata. Selection of the study districts in each stratum should be unbiased for which, the districts in each stratum may be listed from higher to lower API and then divided further in two subgroups of almost equal number of districts, one districts from upper half and one from the lower half in each zone may be selected. Sample size should be calculated based on lowest prevalence. This sample size may be applied to higher prevalence district in each of the zones for uniformity. Since prevalence of malaria has shown significant reduction in the years 2018 and 2019 in Odisha, sample size calculation should be based on current prevalence/incidence for representativeness and not based on 2016 data.

2. Introduction: Authors have stated ‘This initiative saw huge investment of public fund from the state government.’ How much per capita was invested, may be mentioned?

3. “At least 1 ml of intra- venous blood specimen will be collected for malaria and haemoglobin analysis and anthropometric measurements will be recorded from all the members of the sampled household present at the time of interview.”

Considering only two years of implementation of DAMaN, what is the rationale of taking anthropometric measurements? What difference DAMaN would have made in a short span to these features, is not understood? Hence this objective may be dropped and focus should be primarily on the epidemiological impact.

4. What definition of an asymptomatic case will be used? Will temperature be taken at the time of house visit?

5. Where is P. malariae in the whole scheme? This species has been reported from Odisha with decent prevalence in some districts as in previous studies. [The prevalence of P. malariae in Odisha, India by Pati et. al., Tropical Biomedicine 34(3): 607–614 (2017)]

6. The rationale for using three diagnostic methods may be clearly stated in view of Pfhrp-2 gene deletion which ranges from 5-10%; e.g. what is missed by RDT could be captured by microscopy and the PCR will capture low/sub-microscopic parasitaemia which the above two methods may miss detection.

7. On page 15, objective (d), Remove `prevalence’ to assess the outcome of maternal and child health.

8. On page 15, explain outcome assessment from MSAT? (Use Primary data/Generate data)

9. On page 16, Aim 3: Explain about stratification in detail in methodology.

10. On page 17, Sample size: Based on the calculated sample size, you should include 2228 household with pregnant women not household only.

11. On page 22, Statistical analysis: Anaemia should be defined separately for pregnant women, children and general population in a tabular form. It is not clear.

12. Authors will need to calculate sample size separately for LLIN usage (No. of Household) and child health outcome (<5 years)

Reviewer #2: Since 2017, the Indian National Vector-borne Disease Control Programme (NVBDCP) has implemented an intervention project (called DAMaN) to eliminate malaria in the hard-to-reach areas of high malaria-burden district of Odisha State, located on the south-eastern coast of the country.

Madhusmita Bal and colleagues are now proposing an evaluation study of the DAMaN project, in order to establish a continuous assessment of its effectiveness. This proposed DAMaN Assessment will provide evidence on the impact and outcome of intervention based on reduction in overall parasite load and reduction/interruption in transmission and changes in important key health indicators.

The strategies used in the DAMaN project to eliminate malaria in the target areas are not innovative. All of them were based on WHO guidelines for the elimination of malaria transmission. However, the evaluation methodology proposed by the authors of this manuscript brings a new tool to the malaria control and elimination strategies.

The rationale of this registered report protocol is clear, relevant and valid. The study protocol is well written and the methodology stated the authors hypotheses. The sample size was properly calculated. The strategies to analyse the results of the DAMaN Assessment study consider proposals for adequate, robust and well-characterized statistical models.

Despite the clarity of the study protocol submitted, it was not evident how the authors will analyse some variables provided for in the DAMaN Project. In the main objectives of the DAMaN Assessment the authors stated that they will estimate the mass screening and treatment (MSAT), vector control measures (LLIN and/or IRS) and community mobilization and participation. However, no detailed information was presented on how variables related to vector control measures (LLIN usage, for example) and community mobilization and participation will be measured to be included in the difference analysis models.

Da mesma forma, não está claro se os autores irão avaliar outras variáveis importantes na avaliação do controle da malária, tais como a variação anual da chuva e a flutuação da densidade vetorial na área estudada.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Sep 8;15(9):e0238323. doi: 10.1371/journal.pone.0238323.r002

Author response to Decision Letter 0


30 Jul 2020

Response to reviewers

Response to points raised by academic editor

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Answer1: The manuscript submitted, meets the PLOS ONE’s style requirements. The files have been named in the prescribed style as well.

2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information."

Answer 2: The questionnaire has been attached as “supportive information”.

3. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria applied to participant recruitment, c) descriptions of where participants will be recruited and where the research will take place.

Answer 3:

a) Each round of survey will be conducted within August to November, which synchronizes with the period for DAMaN implementation

b) The inclusion/exclusion criteria have been defined and necessary edits made in the text.

c) With regards to the location of the research we will select six districts of the Indian state of Odisha which are clearly mentioned in Figure 2 (currently modified as per the suggestions of 1st Reviewer). These will be selected in due course of time.

The above statements have been included in the mansucript

Moreover, in ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records (DAMaN project data) that will be used in the retrospective part of study. Specifically, please ensure that you have discussed whether all data will be fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.'

DAMaN project data will be extracted in aggregate form and no individual-level data will be retrieved or used, therefore there is no need for de-identification of DAMaN project data. There is also no plan to access patient medical records. This has been included in the manuscript in the relevant section. However, for household survey we have included in the manuscript the standard statement for acquiring consent and deidentifying raw data

4. PLOS ONE does not permit references to unpublished data; therefore, we request that you either include the referenced data or remove the instances of "data not shown," "unpublished results," or similar.

Answer 4: We have cited a website supporting this statement and removed the “unpublished results”

5. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

a) The name of the colleague or the details of the professional service that edited your manuscript

b) A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

c) A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

Answer 5: Our colleague, Dr. Ambarish Dutta, has done thorough copyediting of the manuscript for language usage, spelling and grammar.

6. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Answer6: We have made changes to our Data Availability statement, which has been described in the cover letter also

Comments from 1st Reviewer

Figure 2 suggests that two districts are already selected from each of the three strata. Selection of the study districts in each stratum should be unbiased for which, the districts in each stratum may be listed from higher to lower API and then divided further in two subgroups of almost equal number of districts, one districts from upper half and one from the lower half in each zone may be selected. Sample size should be calculated based on lowest prevalence. This sample size may be applied to higher prevalence district in each of the zones for uniformity. Since prevalence of malaria has shown significant reduction in the years 2018 and 2019 in Odisha, sample size calculation should be based on current prevalence/incidence for representativeness and not based on 2016 data.

Answer1: “Selection of 2 DAMaN- implementing districts from each region of Odisha- Northern, Central, Southern; Six districts in total. Within each region, the first district will be selected from those having above median API and the second to be selected from below median API".

This above text within quotes will be now included in Figure 2 that explains the sampling method and design. We are grateful to the reviewer for suggesting an extra layer of stratification (based on API) to make selection of districts really unbiased, hence, the selection is to be carried out now as per the newly suggested method.

However, the sample size has been calculated for all the six districts together and not for individual district as the study objective is to compute pooled estimates mainly and not at district-wise estimates. Moreover, the DAMaN-implementing blocks and Sub-centres have similar transmission intensity so district or sub-district-wise sample size calculation for lower units may not be needed based on variances in incidence. In this context the rarest prevalence that is parasitaemia among pregnant/lactating women had been chosen as the basis for calculating sample size and it is assumed that this prevalence will be roughly similar in DAMaN-implementing pockets of the state.

Additionally, the malaria prevalence data is not routinely collected by the malaria programme so cannot be the basis of sample size calculation. Consequently, the malaria case detection (monthly/yearly) rate (also known as monthly/yearly parasite incidence) which is a proxy for incidence of malaria has formed the basis for selection hotspots by DAMaN, and the year chosen by DAMaN planners was 2016. Therefore, the DAMaN Assessment exercise has also decided to select 2016 as the basis year for sampling. We would like to adhere to this methodology and not select the years 2018 and 2019 as basis years for sampling, during which period there was decline in malaria cases across the state.

2. Introduction: Authors have stated ‘This initiative saw huge investment of public fund from the state government.’ How much per capita was invested, may be mentioned?

Answer 2: Agreed, the exact statement of expenditure has been mentioned in the manuscript

3. “At least 1 ml of intra- venous blood specimen will be collected for malaria and haemoglobin analysis and anthropometric measurements will be recorded from all the members of the sampled household present at the time of interview.”

Considering only two years of implementation of DAMaN, what is the rationale of taking anthropometric measurements? What difference DAMaN would have made in a short span to these features, is not understood? Hence this objective may be dropped and focus should be primarily on the epidemiological impact.

Answer 3:

We would like to include this component for the following reasons

• This anthropometric data may work as a baseline data for future impact evaluation

• We can compare with state anthropometric averages generated by DHS data and understand the situation in DAMaN pockets

4. What definition of an asymptomatic case will be used? Will temperature be taken at the time of house visit?

Answer 4: Self reported data of history of fever in the family in last two weeks before the date of survey will be collected in-order to understand the prevalence of symptomatic malaria. Temperature recording will not be carried out during the survey.

5. Where is P. malariae in the whole scheme? This species has been reported from Odisha with decent prevalence in some districts as in previous studies. [The prevalence of P. malariae in Odisha, India by Pati et. al., Tropical Biomedicine 34(3): 607–614 (2017)]

Answer 5: As mentioned in the manuscript (Page 16), we would assess the prevalence of P. malariae in this study. The diagnosis will be done by using species specific Polymerase Chain Reaction (PCR) as described in the methodology.

6. The rationale for using three diagnostic methods may be clearly stated in view of Pfhrp-2 gene deletion which ranges from 5-10%; e.g. what is missed by RDT could be captured by microscopy and the PCR will capture low/sub-microscopic parasitaemia which the above two methods may miss detection.

Answer 6: Agreed to the comment. As suggested the rational behind using three diagnostic methods, namely Rapid Diagnostic Test (RDT), blood smear microscopy, polymerase chain reaction (PCR) will be used to find the prevelance of malarial parasite in the blood specimen collected. This modus-operandi will ensure an exhaustive investigation for detecting parasitaemia. The Histidine-Rich Protein 2 (PfHRP2) gene deletion in Plasmodium falciparum leads to no-detection in RDT, however Pf prevalence in those cases can be captured using microscopy and PCR. The PCR method will also be helpful in detecting parasite at sub-microscopic level, which usually gets missed out by RDT and Microscopy. The same reason three different methods have been incorporated in the text, as suggested.

7. On page 15, objective (d), Remove `prevalence’ to assess the outcome of maternal and child health.

Answer 7: Done. “Prevalence” removed.

8. On page 15, explain outcome assessment from MSAT? (Use Primary data/Generate data)

Answer8: Coverage of MSAT, a component of DAMaN will be estimated along with MSAT’s test positivity rate, proportion of asymptomatics among positives etc. This will be done from DAMaN project data that is secondary data.

9. On page 16, Aim 3: Explain about stratification in detail in methodology.

Answer 9: Sub-centres will be stratified into tertiles based on their DAMaN MSAT coverage and then interrupted time series analysis and difference-in-difference analyses will be carried out in these three strata based on the hypothesis that greater coverage of MSAT will lead to greater decline of malaria. Now expanded in manuscript.

10. On page 17, Sample size: Based on the calculated sample size, you should include 2228 household with pregnant women not household only.

Answer 10: Agreed and that will be done

11. On page 22, Statistical analysis: Anaemia should be defined separately for pregnant women, children and general population in a tabular form. It is not clear.

Answer 11: Thanks again for this very valuable suggestion. Done in the manuscript

12. Authors will need to calculate sample size separately for LLIN usage (No. of Household) and child health outcome (<5 years)

Answer 12: LLIN penetration and usage are reasonably high in these DAMaN areas from current anecdotal information. The current sample will suffice to estimate the LLIN-related proportions with enough precision.

The same logic applies for under-5 children as this large sample size is adequate enough to estimate precise childhood health outcome given further that these health outcomes (such as undernutrition and anaemia) are not at all rare, rather rampant in these hotspots. Moreover, almost every household in these areas will have one under-5 given the current fertility pattern of this population. So, the current sampled household will suffice all the purposes.

Review from 2nd reviewer

In the main objectives of the DAMaN Assessment the authors stated that they will estimate the mass screening and treatment (MSAT), vector control measures (LLIN and/or IRS) and community mobilization and participation. However, no detailed information was presented on how variables related to vector control measures (LLIN usage, for example) and community mobilization and participation will be measured to be included in the difference analysis models.

Answer: We are extremely grateful to the kind and encouraging words of 2nd reviewer.

In answer to the query these indicators that were mentioned will be estimated using descriptive statistics initially. However, there variations may be modelled against probable explanatory variables, post hoc, if any interesting findings emerge from the descriptive tables.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Luzia Helena Carvalho

14 Aug 2020

Assessment of effectiveness of DAMaN : A malaria intervention program initiated by Government of Odisha, India

PONE-D-20-12484R1

Dear Dr. Ranjit,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Luzia Helena Carvalho, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: All my comments and questions made in the first revision of this manuscript were properly argumented or answered by the authors.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Acceptance letter

Luzia Helena Carvalho

19 Aug 2020

PONE-D-20-12484R1

Assessment of Effectiveness of DAMaN: A Malaria Intervention Program Initiated by Government of Odisha, India

Dear Dr. Ranjit:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Luzia Helena Carvalho

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Survey questionnaire.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data from this study will be made available upon study completion.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES